The Life Sciences team represented Rubius Therapeutics in its successful completion of a $100 million crossover financing. In just under nine months, Rubius has raised over $220 million.
Rubius has developed the technology to grow, genetically engineer and mature long-circulating Red-Cell Therapeutics™ (RCT™) products, which have the potential to provide transformational clinical benefits to a wide range of patients across multiple therapeutic areas. Proceeds from the financing will be used to accelerate the development of the company’s portfolio of RCTs™ towards clinical proof-of-concept, and to enhance its manufacturing capacity and capabilities.
For more details on the financing, please read the press release.